Cabaletta Bio (CABA) Competitors $1.61 +0.01 (+0.38%) Closing price 07/3/2025 03:47 PM EasternExtended Trading$1.64 +0.04 (+2.43%) As of 07/3/2025 04:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CABA vs. BNTC, ATXS, LIMN, LFCR, OLMA, AARD, IVA, GOSS, OCGN, and GLUEShould you be buying Cabaletta Bio stock or one of its competitors? The main competitors of Cabaletta Bio include Benitec Biopharma (BNTC), Astria Therapeutics (ATXS), Liminatus Pharma (LIMN), Lifecore Biomedical (LFCR), Olema Pharmaceuticals (OLMA), Aardvark Therapeutics (AARD), Inventiva (IVA), Gossamer Bio (GOSS), Ocugen (OCGN), and Monte Rosa Therapeutics (GLUE). These companies are all part of the "pharmaceutical products" industry. Cabaletta Bio vs. Its Competitors Benitec Biopharma Astria Therapeutics Liminatus Pharma Lifecore Biomedical Olema Pharmaceuticals Aardvark Therapeutics Inventiva Gossamer Bio Ocugen Monte Rosa Therapeutics Cabaletta Bio (NASDAQ:CABA) and Benitec Biopharma (NASDAQ:BNTC) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, valuation, earnings, risk and dividends. Does the media refer more to CABA or BNTC? In the previous week, Benitec Biopharma had 1 more articles in the media than Cabaletta Bio. MarketBeat recorded 1 mentions for Benitec Biopharma and 0 mentions for Cabaletta Bio. Cabaletta Bio's average media sentiment score of 0.00 equaled Benitec Biopharma'saverage media sentiment score. Company Overall Sentiment Cabaletta Bio Neutral Benitec Biopharma Neutral Which has more risk & volatility, CABA or BNTC? Cabaletta Bio has a beta of 2.7, meaning that its share price is 170% more volatile than the S&P 500. Comparatively, Benitec Biopharma has a beta of 0.37, meaning that its share price is 63% less volatile than the S&P 500. Do analysts rate CABA or BNTC? Cabaletta Bio currently has a consensus price target of $14.43, indicating a potential upside of 798.42%. Benitec Biopharma has a consensus price target of $23.83, indicating a potential upside of 81.38%. Given Cabaletta Bio's higher possible upside, equities research analysts plainly believe Cabaletta Bio is more favorable than Benitec Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cabaletta Bio 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.00Benitec Biopharma 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.22 Which has better valuation & earnings, CABA or BNTC? Benitec Biopharma has higher revenue and earnings than Cabaletta Bio. Benitec Biopharma is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCabaletta BioN/AN/A-$115.86M-$2.54-0.63Benitec Biopharma$80K4,311.56-$21.75M-$1.51-8.70 Do institutionals and insiders believe in CABA or BNTC? 52.2% of Benitec Biopharma shares are held by institutional investors. 11.3% of Cabaletta Bio shares are held by company insiders. Comparatively, 1.3% of Benitec Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Is CABA or BNTC more profitable? Benitec Biopharma's return on equity of -38.26% beat Cabaletta Bio's return on equity.Company Net Margins Return on Equity Return on Assets Cabaletta BioN/A -78.29% -65.68% Benitec Biopharma N/A -38.26%-35.71% SummaryBenitec Biopharma beats Cabaletta Bio on 10 of the 14 factors compared between the two stocks. Get Cabaletta Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for CABA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CABA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CABA vs. The Competition Export to ExcelMetricCabaletta BioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$82.71M$2.91B$5.53B$9.05BDividend YieldN/A2.44%5.24%4.03%P/E Ratio-0.6321.5627.5220.22Price / SalesN/A281.76421.02118.64Price / CashN/A42.7336.8958.07Price / Book0.517.518.045.67Net Income-$115.86M-$55.05M$3.18B$249.13M7 Day Performance2.29%4.61%2.90%3.28%1 Month Performance-26.33%4.72%3.70%5.55%1 Year Performance-77.22%5.92%36.15%21.12% Cabaletta Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CABACabaletta Bio1.7191 of 5 stars$1.61+0.4%$14.43+798.4%-78.7%$82.71MN/A-0.6350BNTCBenitec Biopharma1.6103 of 5 stars$11.78+3.8%$23.83+102.3%+48.6%$309.23MN/A-7.8020High Trading VolumeATXSAstria Therapeutics1.941 of 5 stars$5.44-2.3%$30.00+451.5%-35.4%$307.00MN/A-2.9130News CoverageLIMNLiminatus PharmaN/A$11.60+22.4%N/AN/A$301.72MN/A0.00N/AGap UpLFCRLifecore Biomedical1.0508 of 5 stars$8.11-1.0%$8.00-1.4%+62.9%$300.31M$128.26M-5.59690OLMAOlema Pharmaceuticals1.7576 of 5 stars$4.34-6.1%$24.50+464.5%-58.8%$296.94MN/A-2.1670Positive NewsAARDAardvark TherapeuticsN/A$13.68+2.2%$33.00+141.2%N/A$296.86MN/A0.0018Analyst RevisionGap UpIVAInventiva2.7833 of 5 stars$3.04-0.3%$10.40+242.1%+3.0%$290.81M$9.95M0.00100News CoverageGap UpGOSSGossamer Bio3.7798 of 5 stars$1.25flat$7.33+486.7%+18.9%$284.13M$114.70M-5.43180OCGNOcugen1.0196 of 5 stars$0.97-1.4%$6.00+518.4%-41.1%$283.36M$4.05M-5.1180High Trading VolumeGLUEMonte Rosa Therapeutics1.3753 of 5 stars$4.57-0.7%$15.33+235.5%+29.7%$281.10M$75.62M57.1390News Coverage Related Companies and Tools Related Companies BNTC Competitors ATXS Competitors LIMN Competitors LFCR Competitors OLMA Competitors AARD Competitors IVA Competitors GOSS Competitors OCGN Competitors GLUE Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CABA) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredThe mainstream media is wrong about AI — againThe mainstream media got it wrong … yet again. AI has recently turned the tech world on its head. And th...Weiss Ratings | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cabaletta Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cabaletta Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
